Last reviewed · How we verify
NCT05909020
EVEREST-HN 1: EVolution of a patiEnt-REported Symptom-based Risk Stratification sySTem
trial testing No intervention. in Head and Neck Cancer in 165 participants. Status unknown.
30 November 2023
Quick facts
| Lead sponsor | Royal Marsden NHS Foundation Trust |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 165 |
| Start date | 17 March 2023 |
| Primary completion | 30 November 2023 |
| Estimated completion | 30 November 2023 |
| Sites | 4 locations across United Kingdom |
Drugs / interventions tested
- No intervention.
Conditions studied
- Head and Neck Cancer — all drugs for Head and Neck Cancer →
Sponsor
Royal Marsden NHS Foundation Trust
Who can join
18 and older, any sex, with Head and Neck Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Can a patient-reported symptom-based risk stratification system improve the suspected head and neck cancer (HNC) pathway? Our methodology includes six interlinked work packages to deliver our aim, with EVEREST-HN 1 encompassing the first of these and seeking to optimise a patient-reported symptom inventory for HNC and outline requirement specification for the SYmptom iNput Clinical (SYNC) system.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05909020
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No intervention.
Trials testing the same drug.
- NCT06843863 — The Effects of Smartphone Addiction on Pinch Strength, Muscle Stiffness, and Hand/Wrist Function in Young Adults · recruiting
- NCT07084883 — Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneratio · recruiting
- NCT06427018 — Expressions of Ezrin and Pip5k1α Proteins in Airway Smooth Muscle of Asthmatic Patients · recruiting
- NCT06134739 — Arterial Embolism After Catheter Ablation of Atrial Fibrillation. ATRIAL FIBRILLATION · unknown
- NCT05963126 — Fetuin A as a Predictor of Deterioration of Renal Function in Hypertonic Patients · recruiting
Other recruiting trials for Head and Neck Cancer
Currently open trials in the same condition.
- NCT07318220 — Prehabilitation Protocol for Head and Neck Cancer Patients · NA · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07467083 — Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Unde · Phase 3 · recruiting
- NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
- NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting
Other Royal Marsden NHS Foundation Trust trials
Trials by the same sponsor.
- NCT07407686 — Improving Engagement From Underserved Communities With Prostate Cancer Genetics Services · not yet recruiting
- NCT07243834 — Assessing a Digital Exercise Intervention for Health Outcomes and Engagement in Regular Exercise · NA · recruiting
- NCT06605833 — CARDiac Toxicity Following ImmunOtherapy Treatment for Melanoma · enrolling by invitation
- NCT07008742 — Feasibility Study of Tissue and Blood Collection in Oncogene-addicted and Neoadjuvantly Treated Non Small Cell Lung Canc · recruiting
- NCT06560905 — Preoperative Planning With PSMA-PET in Melanoma Surgery Trial · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05909020 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Royal Marsden NHS Foundation Trust
- Last refreshed: 3 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05909020.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing